Posters and e-posters 2023

PFF Summit - Interim Analysis of AIR - An Open-label, Single Arm, 36-week Phase 2a Trial of the Angiotensin II Type 2 Receptor Agonist (ATRAG), C21, in Individuals with IPF

Download picture

PFF Summit - ASPIRE – a patient friendly trial evaluating whether C21 improves lung function in IPF

Download picture

PFF Summit - A personalized treatment for anxiety and challenges of living with Pulmonary Fibrosis

Download picture

ERS 2023 - Characterization of high responders in the phase 2a IPF AIR trial of C21 using baseline quantitative CT image analysis

Download picture

ERS 2023 - An open label, pharmacodynamic trial investigating vascular effects of the angiotensin II type 2 receptor agonist (ATRAG) C21

Download picture

ATS 2023 - Development of angiotensin II type 2 receptor agonists (ATRAGs) for treatment of pulmonary fibrosis and pulmonary hypertension

Download picture

ATS 2023 - A digital therapeutic for anxiety symptoms in patients with IPF

Download picture

ATS/RIS 2023 - Vicore - we have a vision to stop disease progression and restore function - that’s why we are unlocking the potential of a new class of drugs

Download picture